Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid TumorsJoachim Drevs, Clemens Unger, Patrizia Siegert et al.|Journal of Clinical Oncology|2007Cited by 303
Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancerM. Lehnert, H. Küpper, K. Mross et al.|British Journal of Cancer|1998Cited by 32
Dexverapamil to overcome epirubicin resistance in advanced breast cancerBeat Thürlimann, M. Lehnert, Nicolaus Kröger et al.|Journal of Cancer Research and Clinical Oncology|1995Cited by 14
361 Dexverapamil to overcome anthracycline-resistance in advanced breast cancerNicolaus Kröger, Dieter K. Hossfeld, M. Lehnert et al.|European Journal of Cancer|1995Cited by 2
Band 23, Heft 6, Dezember 2000T. Kühn, Christoph Kahl, R. Kreienberg et al.|Oncology Research and Treatment|2000Cited by 0